Vanguard Group Inc. Boosts Position in Hims & Hers Health, Inc. $HIMS

Vanguard Group Inc. increased its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 7.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,925,666 shares of the company’s stock after buying an additional 1,407,651 shares during the period. Vanguard Group Inc. owned 0.09% of Hims & Hers Health worth $679,456,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in HIMS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after buying an additional 78,543 shares during the period. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health in the 1st quarter worth about $30,000. EverSource Wealth Advisors LLC increased its stake in Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after buying an additional 687 shares during the period. Amundi increased its stake in Hims & Hers Health by 5.3% in the 2nd quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after buying an additional 522 shares during the period. Finally, California Public Employees Retirement System increased its stake in Hims & Hers Health by 9.5% in the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock worth $16,880,000 after buying an additional 29,471 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity

In other news, CFO Oluyemi Okupe sold 19,645 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $29.96, for a total value of $588,564.20. Following the sale, the chief financial officer directly owned 262,954 shares in the company, valued at approximately $7,878,101.84. This trade represents a 6.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares in the company, valued at $216,086.88. This represents a 38.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 204,857 shares of company stock valued at $5,285,706 over the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research note on Tuesday, March 10th. Leerink Partners raised their target price on shares of Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research report on Friday, March 27th. BTIG Research downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Finally, Citigroup raised shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and raised their target price for the company from $13.25 to $24.00 in a research report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $32.53.

Hims & Hers Health Trading Down 0.2%

NYSE HIMS opened at $27.36 on Monday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The company has a market capitalization of $6.24 billion, a price-to-earnings ratio of 53.65, a price-to-earnings-growth ratio of 2.84 and a beta of 2.43. The company’s 50-day simple moving average is $21.91 and its two-hundred day simple moving average is $30.40. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.11 EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.56 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.